impaired hydroxylation methylcytosine myeloid cancers mutant tet2 
tet2 close relative tet1 enzyme converts methylcytosine 5mc hydroxymethylcytosine 5hmc dna gene encoding tet2 resides chromosome 4q24 region showing recurrent microdeletions copy-neutral loss heterozygosity cn-loh patients diverse myeloid malignancies somatic tet2 mutations frequently observed myelodysplastic syndromes mds myeloproliferative neoplasms mpn mds/mpn overlap syndromes including chronic myelomonocytic leukaemia cmml acute myeloid leukaemias aml secondary aml saml- show tet2 mutations associated myeloid malignancies compromise catalytic activity bone marrow samples patients tet2 mutations displayed uniformly low levels 5hmc genomic dna compared bone marrow samples healthy controls moreover small hairpin rna shrna-mediated depletion tet2 mouse haematopoietic precursors skewed differentiation towards monocyte/macrophage lineages culture significant difference dna methylation bone marrow samples patients high 5hmc versus healthy controls samples patients low 5hmc showed hypomethylation relative controls majority differentially methylated cpg sites results demonstrate tet2 important normal myelopoiesis suggest disruption tet2 enzymatic activity favours myeloid tumorigenesis measurement 5hmc levels myeloid malignancies may prove valuable diagnostic prognostic tool tailor therapies assess responses anticancer drugs 
